{'fraction_non_alphanumeric': 0.047787610619469026, 'fraction_numerical': 0.04070796460176991, 'mean_word_length': 5.01418439716312, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Which one is superior in predicting 30 and 90 days mortality after COPD exacerbation: DECAF, CURB-65, PSI, DOSE, BAP-65

Introduction: COPD is a major cause of morbidity and mortality worldwide. The major scores associated with the mortality after COPD exacerbations were; DECAF, CURB-65, PSI, BAP-65 and DOSE scores. Objective: We aimed to compare these scores in predicting 30- and 90-day mortality in patients hospitalized with exacerbation of COPD. Methods: The data of patients who were hospitalized with the diagnosis of COPD exacerbation between January 2018 and March 2019 and accepted to participate in the study were prospectively recorded. Results: Age, mean modified-medical-research-council (mMRC) dyspnea score, pleural effusion, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), presence of atrial fibrillation (AF), pCO2 pressure values were found to be significantly higher at both 30 and 90-days mortal group, while hemoglobin, albumin and pH values were significantly lower. DECAF, CURB-65, PSI and BAP-65 scores were significantly higher for both 30 and 90-days mortality, and the DOSE score was not significant.As the severity of DECAF, CURB-65, PSI, and BAP-65 scores increased, the mortality also increased. DECAF, CURB-65, PSI and BAP-65 scores predicted in-hospital, 30 day and 90 day mortality. But, In the multivariate analysis, CURB-65 found (OR 2.968 and 2.284, respectively) superior to others in predicting 30 and 90-days mortality. Conclusions: CURB-65 score is a significant, simple and feasible score for predicting 30 and 90 days mortality in COPD exacerbation and should be routinely used in all patients hospitalized with COPD exacerbation.